 Mae'r cyfle a'r cyflog ymlaes yn ymwybod a'n meddwl i'r ysgolwyddu yma yn mylwma ac Eyl Amelodoses. Yn ymweld, o flwyddyn a'r cyflog wedi mewn cyfle, mae'r cyflog yn rhan o'r cyflog, yn hynny'r amlwg, ac yn llwyster. Ond mae'r cyflog o'r cyflog o'r cyflog o'r cyflog, i'n hynny'r ymryd a'r cyflog o'r hynny'r ymweld, Ie, mae'n ein bod yn dweud beth oedd yn ymweld sydd yn ymweld ymweld yw'n cael ymweld ei wneud yn yr ymdyn nhw. Mae'n ymweld ymweld ymweld yw'r ymweld sydd fynd i'r hynny, sy'n gweld i'r cyfrifennu mylwyddu a'r amlod. Mae'n ymweld i'u pethau a'r gwahau a'r amlodau a'r cyfrifennu ac ymweld i'r cyfrifennu ymweld i'r wneud hynny yn ymweld i'r cyfrifennu ac mae'n ymweld i'r gwahau. If we're not understanding what those needs are, then I think that there's less that we can do about it. So I think PROMs, which are patient-reported outcome measures, give us really great tools to understand and capture the impact that my LOMA and AL and my LOI doses have on patients and their family members and friends and carers. So I think in clinical trials especially it's important to be measuring quality of life and health-related quality of life. I think historically this is part of the experience of treatment and care that have been missed in trials. And I think that if we're not really understanding the impact that a new treatment or a new medicine has on patients and the way that they feel, the side effects, the pain, the kind of worry about taking that treatment, then we're not really going to be able to understand the real kind of holistic impact of a patient taking that treatment or medicine. Again, quality of life will help us understand why patients maybe drop out of trials. So I think if we're not really understanding the impact of taking a treatment within a trial, then we're not going to understand that in the real world either. So I think it's really important that we measure quality of life and health-related quality of life as part of trials so that we can understand the impact of treatments as part of those trials, but also when patients start taking it kind of in the real world. So the main tools that are used in myeloma and AL amyloidosis are the EQ5D5L, which is a very generic tool which is designed to work across conditions. It's a health-related quality of life tool and it's quite short, it's quite simple, but it's a generic tool and it's not designed specifically for myeloma. But it needs to be used for reimbursement organisations to make decisions about healthcare resources and allocations. So I think it needs to be used, but also there are better ones for myeloma. Within myeloma we have the MyPos, which is a health-related quality of life tool. And this is great as it really looks at the impact of myeloma on patients. So instead of asking how do you feel today, kind of good, neutral or not so good, it really asks about the impact that myeloma might have. So it will ask how does diarrhea perhaps affect your kind of day-to-day life. So patients really like it for that reason. We also have the EORTC myeloma tools, which are also very patient-sensitive. And patients really like those tools from myeloma. There is a new tool called the HM Pro, which is designed and led by a research team. It was designed by Professor Sam Sallick, and it's for hematology, but it really worked well in myeloma and AL amyloidosis. So we hope to see these tools being used more in clinical practice and trials in the future.